Overall Survival Analysis Between African-American and Caucasian Men with mCRPC

Susan Halabi, PhD
Published: Friday, Aug 17, 2018



Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses an analysis of overall survival (OS) between African-American and Caucasian men with metastatic castration-resistant prostate cancer (mCRPC).

Historically, reports have suggested that African-American men experience a shorter OS compared with Caucasian men. Much of this information is limited due to sample size, which in part is due to the poor access that African-American men have to healthcare, says Halabi. An analysis presented at the 2018 ASCO Annual Meeting aimed to compare OS in African-American and Caucasian men through patient data from 9 phase III clinical trials of a docetaxel- or prednisone-containing regimen.

The analysis evaluated 8,871 patients. In this group of men with mCRPC, 7,528 (85%) patients were Caucasian, 500 (6%) patients were African-American. Findings showed a median OS of 21.0 (95% CI; 19.4-22.5) for African-American patients compared with 21.2 months (95% CI; 20.8-21.7) for Caucasian patients. The hazard ratio was 0.81 favoring African-American men, meaning that the risk of death was about 19% lower for these men, which is contrary to the initial hypothesis, Halabi says.


Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses an analysis of overall survival (OS) between African-American and Caucasian men with metastatic castration-resistant prostate cancer (mCRPC).

Historically, reports have suggested that African-American men experience a shorter OS compared with Caucasian men. Much of this information is limited due to sample size, which in part is due to the poor access that African-American men have to healthcare, says Halabi. An analysis presented at the 2018 ASCO Annual Meeting aimed to compare OS in African-American and Caucasian men through patient data from 9 phase III clinical trials of a docetaxel- or prednisone-containing regimen.

The analysis evaluated 8,871 patients. In this group of men with mCRPC, 7,528 (85%) patients were Caucasian, 500 (6%) patients were African-American. Findings showed a median OS of 21.0 (95% CI; 19.4-22.5) for African-American patients compared with 21.2 months (95% CI; 20.8-21.7) for Caucasian patients. The hazard ratio was 0.81 favoring African-American men, meaning that the risk of death was about 19% lower for these men, which is contrary to the initial hypothesis, Halabi says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x